Fusion protein of human fibroblast growth factor-21 and exendin-4
US8809499B2 · kind B2 · utility
53Cited by
1References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 12, 2010 |
| Grant date | Aug 19, 2014 |
| Priority date | — |
| Expiry date | Mar 14, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a fusion protein, which comprises human fibroblast growth factor 21 and glucagon-like-peptide-1 or its analogs. Also provided is the medicament composition comprising the fusion protein, which can be used for treating or preventing obesity, diabetes, hyperglycemia and hyperlipidemia etc.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.